GAIA and MEDICE sign deal for commercialization of attexis for ADHD in Germany
Digital therapeutics company GAIA has announced the signing of a licensing agreement for attexis® with fellow German firm MEDICE Arzneimittel Pütter.
As one of the leading pharma companies in ADHD, the MEDICE Health Family will use its market know-how and its commercial scale to bring attexis to patients in Germany.
attexis is a personalized, fully-automated digital therapy designed to help adult ADHD patients better manage their symptoms. Its efficacy and safety are currently being studied in a large-scale clinical trial.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountBecome a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
More on this story...
Today's issue
Company Spotlight
More Features in Pharmaceutical
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze